16 October 2024 US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity.
Swiss drugmaker Novartis has launched legal action against the US government, after administrators revealed the first drugs to be subject to pricing regulations mandated by the Inflation Reduction Act (IRA). 7 September 2023
Japanese pharma major Astellas Pharma revealed that it has requested that the Court dismiss the company’s lawsuit challenging the constitutionality of certain provisions of the US government’s Inflation Reduction Act (IRA). 7 September 2023
Cardiometabolic med Jardiance (empagliflozin), a blockbuster product developed by Boehringer Ingelheim and Eli Lilly, has picked up a new approval in the UK. 7 September 2023
The National Institute for Health and Care Excellence (NICE) has published Final Guidance on a new medicine for the treatment of the most common inherited heart condition in England and Wales. 6 September 2023
The UK is an attractive place to conduct life science research and development (R&D). However, we must caveat this statement with the words, ‘for now’. 6 September 2023
Cambridge, US-based Apollo Therapeutics today announces the close of $226.5 million in a Series C financing led by lead investor Patient Square Capital. 6 September 2023
Marie-France Tschudin, president, innovative medicines international and chief commercial officer of Novartis, has decided to leave the Swiss pharma giant and will step down from the executive committee of Novartis. 6 September 2023
Dr Monica Shaw has joined the commercial leadership team of US pharma major Bristol Myers Squibb’s as senior vice president, major markets. 6 September 2023
The Russian segment of drug public procurements significantly declined this year, mainly as a result of a significant drop of purchases under various state programs, The Pharma Letter’s local correspondent reports. 6 September 2023
Shares of Spanish dermatology-focused drugmaker Almirall rallied yesterday, after the company revealed in a brief stock exchange filing that it is looking to expand its therapeutic range. 5 September 2023
Palforzia was going to be the keystone product in Nestle’s strategic expansion into biotech, but the Swiss food and drink giant has finally thrown in the towel. 5 September 2023
Italy’s privately-held drug developer Italfarmaco Group today revealed that its Marketing Authorization Application (MAA) for Givinostat as a potential treatment for Duchenne muscular dystrophy (DMD) has been submitted to the European Medicine Agency. 5 September 2023
Dutch specialty pharma firm Pleco Therapeutics has appointed Dr Henno Welgemoed in the newly created role of chief medical officer (CMO). 5 September 2023
Privately-held Italian drugmaker Angelini Pharma today shared positive findings from post-hoc analyses of the C017 open-label extension (OLE) study. 4 September 2023
Shares of Australian specialty pharma firm Mayne Pharma Group closed up 9.2% at A$3.68 today, after it released full-year fiscal 2023 financials, showing that reported revenues were A$183.6 million (US$118.5 million), up 17% on FY 2022. 4 September 2023
AbbVie has announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Aquipta (atogepant) for the prophylaxis of migraine in adults who have at least four migraine days per month. 4 September 2023
Since first demonstrating clinical success in the treatment of obesity, Wegovy (semaglutide) has garnered ever increasing amounts of interest from patients, providers and investors alike. 4 September 2023
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.